Parliamentary questions

Questions

TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work

Browse the questions

Clear

27,342 questions match, newest first.

Martin Kenny Written 26 May 2026 · to Health
1125. Deputy Martin Kenny asked the Minister for Health the cost of establishing each integrated healthcare area; and the projected annual cost of operating each integrated healthcare area compared to community healthcare organisations. [38801/26]
Malcolm Byrne Written 26 May 2026 · to Health
1126. Deputy Malcolm Byrne asked the Minister for Health the mechanisms in place in her Department to ensure delivery on the commitments in the Programme for Government; the civil servant specifically responsible for overseeing such delivery; the measures that are used to assess progress; and if she will make a statement on the matter. [38815/26]
Tom Brabazon Written 26 May 2026 · to Health
1127. Deputy Tom Brabazon asked the Minister for Health the timeline for a decision by the HSE drugs group regarding the reimbursement of risdiplam for adults living with spinal muscular atrophy. [38838/26]
Ken O'Flynn Written 26 May 2026 · to Health
1128. Deputy Ken O'Flynn asked the Minister for Health whether any HSE national policy, clinical guideline, serious incident framework, or safety protocol explicitly references signs of life following termination of pregnancy. [38839/26]
Ken O'Flynn Written 26 May 2026 · to Health
1129. Deputy Ken O'Flynn asked the Minister for Health whether any hospital is required to notify the HSE National Incident Management Team where signs of life are observed following termination of pregnancy. [38840/26]
Ken O'Flynn Written 26 May 2026 · to Health
1130. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has classified any such event as a serious reportable event, serious incident, or notifiable patient safety incident since 2019. [38841/26]
Ken O'Flynn Written 26 May 2026 · to Health
1131. Deputy Ken O'Flynn asked the Minister for Health whether her Department has sought legal advice regarding statutory reporting obligations in such cases. [38842/26]
Ken O'Flynn Written 26 May 2026 · to Health
1132. Deputy Ken O'Flynn asked the Minister for Health whether HIQA has any inspection, governance, or oversight role in relation to such incidents. [38843/26]
Malcolm Byrne Written 26 May 2026 · to Health
1133. Deputy Malcolm Byrne asked the Minister for Health if there will be an independent assessment within the HSE of the pension entitlements of a person (details supplied); and if she will make a statement on the matter. [38844/26]
Ken O'Flynn Written 26 May 2026 · to Health
1134. Deputy Ken O'Flynn asked the Minister for Health the division of the HSE or Department of Health that holds responsibility for estimating the number of patients clinically eligible for orphan medicinal products approved for reimbursement in the State (details supplied). [38846/26]
Ken O'Flynn Written 26 May 2026 · to Health
1135. Deputy Ken O'Flynn asked the Minister for Health if any budget impact assessment, cost projection, prevalence estimate, or epidemiological model was prepared in advance of reimbursement consideration for omaveloxolone (skyclarys); and the details of same. [38847/26]
Ken O'Flynn Written 26 May 2026 · to Health
1136. Deputy Ken O'Flynn asked the Minister for Health if the HSE maintains a national registry, prevalence estimate or centrally collated dataset for Friedreich's ataxia patients in the State. [38848/26]
Ken O'Flynn Written 26 May 2026 · to Health
1137. Deputy Ken O'Flynn asked the Minister for Health how reimbursement decisions for high-cost orphan medicines are financially planned where the HSE does not centrally retain data regarding the number of clinically eligible patients. [38849/26]
Ken O'Flynn Written 26 May 2026 · to Health
1138. Deputy Ken O'Flynn asked the Minister for Health if the National Centre for Pharmacoeconomics, the HSE medicines management programme, or any external body estimated the likely eligible patient cohort for omaveloxolone (skyclarys) prior to reimbursement consideration. [38850/26]
Ken O'Flynn Written 26 May 2026 · to Health
1139. Deputy Ken O'Flynn asked the Minister for Health if any hospitals, hospital groups, or specialist neurology centres currently facilitate access to omaveloxolone (skyclarys) through named-patient arrangements, manufacturer-supported supply, or exceptional approval mechanisms outside PCRS reimbursement pathways. [38854/26]
Ken O'Flynn Written 26 May 2026 · to Health
1140. Deputy Ken O'Flynn asked the Minister for Health if the HSE maintains any national policy governing interim patient access to medicines awaiting reimbursement decisions for rare diseases. [38855/26]
Ken O'Flynn Written 26 May 2026 · to Health
1141. Deputy Ken O'Flynn asked the Minister for Health if the Department or HSE has examined establishing a formal compassionate or early-access medicines framework for patients with rare progressive conditions pending health technology assistant and reimbursement determinations. [38856/26]
Ken O'Flynn Written 26 May 2026 · to Health
1142. Deputy Ken O'Flynn asked the Minister for Health the number of reimbursement applications for orphan or ultra-orphan medicines remain under assessment by the HSE for more than 12 months as of May 2026. [38857/26]
Ken O'Flynn Written 26 May 2026 · to Health
1143. Deputy Ken O'Flynn asked the Minister for Health if the HSE records the number of patients who seek access to medicines through named-patient or exceptional approval mechanisms outside standard reimbursement arrangements. [38858/26]
Ken O'Flynn Written 26 May 2026 · to Health
1144. Deputy Ken O'Flynn asked the Minister for Health whether any patient safety review, adverse incident review, or clinical governance review has examined the impact of prolonged ambulance dispatch or allocation delays on patient outcomes since 2020; and if so, to provide details. [38862/26]
Ken O'Flynn Written 26 May 2026 · to Health
1145. Deputy Ken O'Flynn asked the Minister for Health whether the National Ambulance Service operates under any internally defined escalation thresholds for excessive dispatch delay, delayed resource allocation, or prolonged queue times for emergency incidents; and if so, to provide details. [38863/26]
Ken O'Flynn Written 26 May 2026 · to Health
1146. Deputy Ken O'Flynn asked the Minister for Health whether any review has been conducted regarding whether Ireland's current ambulance dispatch governance framework aligns with international best practice standards in comparable jurisdictions; and if so, to provide details. [38864/26]
Ken O'Flynn Written 26 May 2026 · to Health
1147. Deputy Ken O'Flynn asked the Minister for Health whether any statutory instrument, policy directive, governance framework, operational standard, or national clinical guideline formally defines acceptable maximum ambulance dispatch times in Ireland. [38865/26]
Ken O'Flynn Written 26 May 2026 · to Health
1148. Deputy Ken O'Flynn asked the Minister for Health whether the Department or the HSE maintains any national dataset recording ambulance incidents where dispatch allocation exceeded a specified time threshold; and if not, whether consideration has been given to establishing such reporting mechanisms. [38866/26]
Ken O'Flynn Written 26 May 2026 · to Health
1149. Deputy Ken O'Flynn asked the Minister for Health whether the National Ambulance Service defines any ambulance response delay duration as constituting a potential patient safety incident in and of itself; and if so, the thresholds applied. [38877/26]